Immunotherapy for the Treatment of Advanced Solid Tumor

Sponsor

Tongji Hospital (Other)

Overall Status

Not yet recruiting

CT.gov ID

NCT03658785

Collaborator

(none)

Enrollment

Location

Arm

72.7

Anticipated Duration (Months)

0.6

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

The purpose of this study is to evaluate the safety, side effects and benefits of autologous tumor infiltrating lymphocytes(TIL) specific to personalized Neo-antigens in the treatment of patients with recurrent, metastatic and advanced solid tumors.

Condition or Disease	Intervention/Treatment	Phase
Recurrence Tumor Metastatic Cancer Solid Tumor	Biological: TIL Drug: Aldesleukin Drug: Cyclophosphamide Drug: Fludarabine	Phase 1/Phase 2

Detailed Description

Adoptive cell transfer therapy that utilizes an autologous TIL manufacturing progress is originally developed by the NCI for the treatment of patients with recurrent, metastatic cervical cancer. TILs specific to personalized neo-antigens will be expended in vitro and given back to the patients through vein. A total of 20 patients will be enrolled in the single-arm, open label, interventional study.

Study Design

Study Type:

Interventional

Anticipated Enrollment :

40 participants

Allocation:

N/A

Intervention Model:

Single Group Assignment

Masking:

None (Open Label)

Primary Purpose:

Treatment

Official Title:

Immunotherapy Using Precision T Cells Specific to Personalized Neo-antigen for the Treatment of Advanced Solid Tumor

Anticipated Study Start Date :

Dec 10, 2018

Anticipated Primary Completion Date :

Dec 31, 2023

Anticipated Study Completion Date :

Dec 31, 2024

Arms and Interventions

Arm	Intervention/Treatment
Experimental: TIL,IL-2,Cyclophosphamide,Fludarabine Biological: TIL On day 0, cells will be infused intravenously over 20 to 30 minutes (one to four days after the last dose of fludarabine). Drug: Aldesleukin Aldesleukin 720,000 IU/kg IV (based on total body weight) over 15 minutes approximately every eight hours (+/- 1hr) beginning within 24 hours of cell infusion and continuing for up to 5 days (maximum of 15 doses.) Drug: Cyclophosphamide On day -7 and day -6: Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml D5W over 1 hr. Drug: Fludarabine Days -7 to -3: Fludarabine 25 mg /m2/day IVPB daily over 30 minutes for 5 days.	Biological: TIL On day 0, cells will be infused intravenously over 20 to 30 minutes (one to four days after the last dose of fludarabine) Drug: Aldesleukin Aldesleukin 720,000 IU/kg IV (based on total body weight) over 15 minutes approximately every eight hours (+/- 1hr) beginning within 24 hours of cell infusion and continuing for up to 5 days (maximum of 15 doses.) Other Names: IL-2 Drug: Cyclophosphamide On day -7 and day -6: Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml D5W over 1 hr. Other Names: CTX Drug: Fludarabine Days -7 to -3: Fludarabine 25 mg /m2/day IVPB daily over 30 minutes for 5 days

Arm

Intervention/Treatment

Experimental: TIL,IL-2,Cyclophosphamide,Fludarabine

Biological: TIL On day 0, cells will be infused intravenously over 20 to 30 minutes (one to four days after the last dose of fludarabine). Drug: Aldesleukin Aldesleukin 720,000 IU/kg IV (based on total body weight) over 15 minutes approximately every eight hours (+/- 1hr) beginning within 24 hours of cell infusion and continuing for up to 5 days (maximum of 15 doses.) Drug: Cyclophosphamide On day -7 and day -6: Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml D5W over 1 hr. Drug: Fludarabine Days -7 to -3: Fludarabine 25 mg /m2/day IVPB daily over 30 minutes for 5 days.

Biological: TIL

On day 0, cells will be infused intravenously over 20 to 30 minutes (one to four days after the last dose of fludarabine)

Drug: Aldesleukin

Aldesleukin 720,000 IU/kg IV (based on total body weight) over 15 minutes approximately every eight hours (+/- 1hr) beginning within 24 hours of cell infusion and continuing for up to 5 days (maximum of 15 doses.)

Other Names:

IL-2

Drug: Cyclophosphamide

On day -7 and day -6: Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml D5W over 1 hr.

Other Names:

CTX

Drug: Fludarabine

Days -7 to -3: Fludarabine 25 mg /m2/day IVPB daily over 30 minutes for 5 days

Outcome Measures

Primary Outcome Measures

Objective Responce Rate [6 months after cell infusion]
The Objective Responce Rate of patients received immunotherapy are accesed by the Response Criteria in Solid Tumors (RECIST) v1.0.

Secondary Outcome Measures

Adverse Event [up to 12 months]
Aggregate of all adverse events, as well as their frequency and severity are accessed by the Common Terminology Criteria in Adverse Events (CTCAE v4.03).
Disease Control Rate [up to 12 months]
Disease control rate (DCR) as measured by RECIST 1.1 criteria.
Duration of Response [up to 12 months]
Duration of response (DOR) as measured by RECIST 1.1 criteria .
Progression-Free Survival [up to 12 months]
PFS will be summarized using Kaplan-Meier estimates.
Overall Survival [up to 60 months]
The overall survival of all patients entering the study will be monitored.

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years to 70 Years

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

To be eligible for the study, patients must meet ALL of the following criteria prior to enrollment in the study:

Must be ≥ 18 years of age at the time of consent.
Must have recurrent, metastatic, or persistent carcinoma that is not amenable to curative treatment with surgery and/or radiation therapy and for which no other therapies are expected to have significant benefit, in the opinion of the Investigator.
Must have at least 1 lesion that is resectable for TIL generation. The resected TIL generating lesion(s) should yield at least 1.5 cm in diameter post-resection of tumor tissue. Following resection for TIL generation, must have a remaining measurable target lesion as defined by RECIST v1.1.
Patients must have progressive disease while receiving or after the completion of the most recent prior treatment.
Any prior therapy directed at the malignant tumor must be discontinued at least 28 days prior to tumor resection. Radiation therapy may have been received up to 28 days prior to tumor resection for lesions not expected to be used for TIL generation or target lesions.
Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
Patients must be seronegative for the human immunodeficiency virus (HIV).
Patients with positive serology for hepatitis B virus surface antigen (HBsAg), hepatitis B core antibody (anti-HBc), or hepatitis C virus (anti-HCV) indicating acute or chronic infection may be enrolled if the viral load by polymerase chain reaction (PCR) is undetectable with/without active treatment.
Hematology:

Absolute neutrophil count greater than 1000/mm(3) without the support of filgrastim;White blood cell (WBC) greater than or equal to 3000/mm(3);Platelet count greater than or equal too 100,000/mm(3);Hemoglobin greater than 8.0 g/dl.

Chemistry:

Serum alanine aminotransferase (ALT)/aspartate aminotransferase (AST) less than or equal to to 2.5 times the upper limit of normal. Serum creatinine less than or equal to to 1.6 mg/dl.Total bilirubin less that or equal to 1.5 mg/dl, except in patients with Gilbert's Syndrome who must have a total bilirubin less than 3.0 mg/dl.

Women of child bearing potential must have a negative pregnancy test because of the potentially dangerous effects of the treatment on the fetus.

Exclusion Criteria:

Patients who have received an organ allograft or prior cell transfer therapy.
Patients who are on a systemic steroid therapy > 10 mg of prednisone daily or other steroid equivalent.
Patients who currently have prior therapy-related toxicities greater than Grade 1 according to NCI-CTCAE v4.03; except for peripheral neuropathy, alopecia, or vitiligo prior to enrollment/resection.
Patients who have a contraindication to or history of hypersensitivity reaction to any component or excipients of the TIL therapy and the other study drugs.
Patients with active systemic infections, coagulation disorders or other active major medical illnesses of the cardiovascular, respiratory, or immune system.
Patients with symptomatic and/or untreated brain metastases (of any size and any number).
Patients who have any form of primary or acquired immunodeficiency syndrome, such as severe combined immunodeficiency disease or acquired immune deficiency syndrome (AIDS).
Patients who have a diagnosis of end-stage renal disorder requiring hemodialysis.
Patients who have a left ventricular ejection fraction (LVEF) < 45% or who are New York Heart Association (NYHA) Class 2 or higher.

Patients who have a forced expiratory volume in 1 second (FEV1) of less than or equal to 60% of predicted normal.

Patients who have received a live or attenuated vaccine within 28 days of the NMA-LD regimen.
Patients whose cancer requires immediate treatment or who would otherwise suffer a disadvantage by participating in this study.
Patients who have received prior treatment with immunotherapy (eg, anti-PD-1 anti-PD-L1, or anti-CTLA4 antibodies)